NDAORALPOWDERPriority Review
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
NORVIR (ritonavir) by AbbVie is hiv protease inhibitors [moa]. First approved in 2017.
Drug data last refreshed 22h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral HIV protease inhibitor that blocks HIV replication by inhibiting the protease enzyme required for viral maturation. It is primarily used as a pharmacokinetic booster in combination antiretroviral regimens rather than as a primary antiretroviral agent. Ritonavir works by inhibiting cytochrome P450 3A, which increases and prolongs the blood levels of other protease inhibitors.
$0.753MPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization, suggesting stable maintenance-focused commercial operations rather than growth-stage expansion.
Mechanism of Action
HIV Protease Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
HIV Infections
Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns
24 enrolled
HIV InfectionsPregnancy
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
44 enrolled
HIV Infections
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
HIV Infections
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
55 enrolled
HIV Infections
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.